Literature DB >> 2822362

Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

A Polak1.   

Abstract

Combination pairs of 5-fluorocytosine (5-FC) + itraconazole (Itra), 5-FC + fluconazole (Fluc), and amphotericin B (Amph B) + Itra were administered to mice with experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis with a variety of combination ratios. The life-prolonging effect of the combinations was compared with the effect of each partner administered alone and with a double dosage. Using the U test of Mann and Whitney, the effects of the concentration were classified as synergistic, additive, indifferent or antagonistic; the degree of the interaction was compared with the known effect of Amph B and 5-FC combinations. The combination 5-FC + Itra was definitely synergistic or additive in candidiasis and aspergillosis. The most pronounced synergism occurred in the infection with a 5-FC-resistant strain of Candida albicans. The degree of synergism was the same as with 5-FC + Amph B. In cryptococcosis this combination was indifferent. The combination of 5-FC + Itra merits clinical investigation, especially in candidiasis and aspergillosis. Amph B + Itra was mostly indifferent and weakly antagonistic; the degree of antagonism was significantly weaker than the one observed with Amph B + ketoconazole (Keto). In candidiasis, 5-FC + Fluc was synergistic, but indifferent in cryptococcosis and aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822362     DOI: 10.1159/000238524

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  25 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 3.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 5.  Combination therapy for systemic mycosis.

Authors:  A Polak
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

6.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 8.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

9.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Anna M Schimizzi; Monia Maracci; Daniele Giannini; Flavia Carle; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.